So the bottom line is, we've significantly further de-risked our...

So the bottom line is, we've significantly further de-risked our path to FDA approval, to the point of only having trivial, medial matters left. Wow.

and I think the consensus understands that, because most of the frustration is because of these lame final hurdles to step over.

its a no brainer for me; I've loaded a shovel of cash and awaiting filling in of another order. This is like another involuntary final tree shaking, in my view.

Criticise BOT management all you want, but you can't deny that yesterday's ANN is still significant progress.